Medical oncology · HER2-Positive Breast Cancer

Your Treatment Plan for Early-Stage Disease

At a Glance

For early-stage HER2-positive breast cancer, treatment is tailored to tumor size, lymph-node status, hormone-receptor status, and how the tumor responds. It may combine chemotherapy, HER2-targeted medicines, surgery, radiation, and hormone therapy, with the plan adjusted after surgery.

Treatment for early-stage (Stage I–III) HER2-positive breast cancer is highly individualized. Rather than a “one-size-fits-all” approach, care is increasingly response-adapted, meaning your doctors will observe how your tumor reacts to medicine and adjust your plan to optimize your outcome ^[1].

The Power of “Treatment First” (Neoadjuvant Therapy)

For most patients with tumors larger than 2 centimeters or those whose cancer has spread to the lymph nodes, a standard approach is neoadjuvant therapy—treatment given before surgery ^[2].

This approach offers two major advantages:

Tumor Shrinkage: It can shrink a large tumor, sometimes making it possible to have a lumpectomy (breast-conserving surgery) instead of a mastectomy ^[1].
The “Stress Test”: It acts as an in-body test. By giving the medicine while the tumor is still in place, doctors can see how well the cancer responds to the drugs ^[3].

The standard neoadjuvant regimen typically includes chemotherapy (like a taxane and sometimes carboplatin) combined with a “dual blockade” of two HER2-targeted drugs: trastuzumab and pertuzumab ^[4] ^[1].

Adapting After Surgery: The KATHERINE Protocol

The most critical moment in your treatment plan happens after surgery, when a pathologist examines the removed tissue.

Pathologic Complete Response (pCR): If no invasive cancer is found in the breast or sampled lymph nodes, it indicates a highly favorable response. You will typically continue trastuzumab (and sometimes pertuzumab, depending on your nodal status and tolerance) to complete about one year of treatment ^[5].
Residual Invasive Disease: If some invasive cancer cells remain, your team will likely change your treatment. Based on the landmark KATHERINE trial, switching to a different drug called T-DM1 (trastuzumab emtansine) for 14 cycles significantly reduces the risk of invasive disease recurrence ^[6] ^[7]. In this study, switching to T-DM1 halved the risk of the cancer coming back or death compared to staying on trastuzumab alone, though T-DM1 carries its own side effects and monitoring requirements ^[8].

Specialized Care for Small Tumors

If your tumor is very small and has not spread to the lymph nodes (Stage I), you may have surgery first ^[2].

T1a (≤ 0.5 cm): These tumors have a low absolute risk of returning. Your doctor will individualize your plan, discussing observation versus limited treatment based on age, hormone-receptor status, and your personal preferences ^[9] ^[10].
T1b or T1c (> 0.5 cm to 2 cm): For these small, node-negative tumors, doctors often use a “de-escalated” regimen—such as 12 weeks of the chemotherapy drug paclitaxel along with trastuzumab, followed by trastuzumab maintenance to complete a full year. This provides strong protection with fewer side effects than more intensive regimens ^[1] ^[11].

The Role of Other Treatments

While HER2-targeted therapy is central, other treatments remain essential:

Surgery: Whether you have a lumpectomy or mastectomy, the goal is to remove the tumor and check the lymph nodes ^[1].
Radiation: This is typically used after a lumpectomy or in certain high-risk cases after a mastectomy to treat microscopic cells in the breast or chest wall.
Endocrine (Hormone) Therapy: If your cancer is also HR-positive, you will take hormone-blocking therapy (like tamoxifen or an aromatase inhibitor) for 5 to 10 years. The exact timing depends on your menopausal status and other treatments, but it is crucial for preventing long-term recurrence ^[12] ^[13].

Common questions in this guide

Why might treatment begin before surgery for HER2-positive breast cancer?

For tumors larger than 2 centimeters or cancer that has spread to the lymph nodes, doctors commonly use neoadjuvant treatment before surgery. It can shrink the tumor and show how well it responds, which helps guide the treatment given after surgery.

What does a pathologic complete response mean after surgery?

A pathologic complete response means no invasive cancer is found in the removed breast tissue or sampled lymph nodes. People with this response typically continue trastuzumab, with pertuzumab sometimes continued based on lymph-node status and tolerance, to complete about one year of treatment.

What happens if invasive cancer remains after pre-surgery treatment?

If invasive cancer cells remain in the surgical specimen, the treatment plan may change to T-DM1, also called trastuzumab emtansine, for 14 cycles. This approach lowers the risk of invasive cancer returning compared with continuing trastuzumab alone, but it has its own side effects and monitoring needs.

How are very small, node-negative HER2-positive tumors treated?

Stage I tumors may be treated with surgery first. For tumors up to 0.5 centimeters, observation or limited treatment may be considered based on age, hormone-receptor status, and preferences; tumors larger than 0.5 centimeters and up to 2 centimeters often receive a shorter paclitaxel-and-trastuzumab regimen followed by trastuzumab to complete a year.

What roles do surgery and radiation play in early-stage HER2-positive breast cancer?

Surgery removes the breast tumor and checks the lymph nodes, using either lumpectomy or mastectomy when appropriate. Radiation is commonly used after lumpectomy and may also be recommended after mastectomy when features indicate a higher risk of remaining cancer cells.

Will I need hormone therapy if my HER2-positive cancer is also hormone-receptor positive?

Yes, hormone-blocking treatment such as tamoxifen or an aromatase inhibitor is commonly used when the cancer is also hormone-receptor positive. It may be taken for 5 to 10 years, with the timing and duration adjusted for menopausal status and other treatments.

How is heart health monitored during HER2-targeted treatment?

Some HER2-targeted treatments can affect heart function, so clinicians commonly assess and monitor heart health during therapy. The tests and schedule depend on the medicines being used and your medical history, so ask your treatment team what monitoring you need.

Curated prompts to bring to your next appointment.

1.Based on my tumor size and node status, why are you recommending (surgery first/treatment first)?
2.If we start with treatment before surgery (neoadjuvant), how will we measure whether the cancer is responding?
3.What happens if there is still invasive cancer left at the time of my surgery? Will we change my medication?
4.Am I a candidate for a 'de-escalated' or shorter chemotherapy regimen?
5.How will you monitor my heart health while I am on HER2-targeted therapy?
6.If my cancer is also HR-positive, when will I start hormone-blocking therapy, and for how long?

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References (13)

1
Neoadjuvant and adjuvant treatment of patients with HER2-positive early breast cancer.
Harbeck N
Breast (Edinburgh, Scotland) 2022; (62 Suppl 1()):S12-S16 doi:10.1016/j.breast.2022.01.006.
PMID: 35148934
2
Neoadjuvant Chemotherapy, Endocrine Therapy, and Targeted Therapy for Breast Cancer: ASCO Guideline.
Korde LA, Somerfield MR, Carey LA, et al.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2021; (39(13)):1485-1505 doi:10.1200/JCO.20.03399.
PMID: 33507815
3
Neoadjuvant trastuzumab, pertuzumab, and chemotherapy versus trastuzumab emtansine plus pertuzumab in patients with HER2-positive breast cancer (KRISTINE): a randomised, open-label, multicentre, phase 3 trial.
Hurvitz SA, Martin M, Symmans WF, et al.
The Lancet. Oncology 2018; (19(1)):115-126 doi:10.1016/S1470-2045(17)30716-7.
PMID: 29175149
4
Neoadjuvant Pertuzumab-containing Regimens Improve Pathologic Complete Response Rates in Stage II to III HER-2/neu-positive Breast Cancer: A Retrospective, Single Institution Experience.
Murthy RK, Raghavendra AS, Hess KR, et al.
Clinical breast cancer 2018; (18(6)):e1283-e1288 doi:10.1016/j.clbc.2018.07.008.
PMID: 30077429
5
Neoadjuvant Trastuzumab Emtansine and Pertuzumab in Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Three-Year Outcomes From the Phase III KRISTINE Study.
Hurvitz SA, Martin M, Jung KH, et al.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2019; (37(25)):2206-2216 doi:10.1200/JCO.19.00882.
PMID: 31157583
6
FDA Approval Summary: Ado-Trastuzumab Emtansine for the Adjuvant Treatment of HER2-positive Early Breast Cancer.
Wedam S, Fashoyin-Aje L, Gao X, et al.
Clinical cancer research : an official journal of the American Association for Cancer Research 2020; (26(16)):4180-4185 doi:10.1158/1078-0432.CCR-19-3980.
PMID: 32217612
7
Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer.
von Minckwitz G, Huang CS, Mano MS, et al.
The New England journal of medicine 2019; (380(7)):617-628 doi:10.1056/NEJMoa1814017.
PMID: 30516102
8
Selection of Optimal Adjuvant Chemotherapy and Targeted Therapy for Early Breast Cancer: ASCO Guideline Update.
Denduluri N, Somerfield MR, Chavez-MacGregor M, et al.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2021; (39(6)):685-693 doi:10.1200/JCO.20.02510.
PMID: 33079579
9
A US Registry-Based Assessment of Use and Impact of Chemotherapy in Stage I HER2-Positive Breast Cancer.
Parsons BM, Uprety D, Smith AL, et al.
Journal of the National Comprehensive Cancer Network : JNCCN 2018; (16(11)):1311-1320 doi:10.6004/jnccn.2018.7058.
PMID: 30442732
10
Selection of Optimal Adjuvant Chemotherapy Regimens for Human Epidermal Growth Factor Receptor 2 (HER2) -Negative and Adjuvant Targeted Therapy for HER2-Positive Breast Cancers: An American Society of Clinical Oncology Guideline Adaptation of the Cancer Care Ontario Clinical Practice Guideline.
Denduluri N, Somerfield MR, Eisen A, et al.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2016; (34(20)):2416-27 doi:10.1200/JCO.2016.67.0182.
PMID: 27091714
11
Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer: final 10-year analysis of the open-label, single-arm, phase 2 APT trial.
Tolaney SM, Tarantino P, Graham N, et al.
The Lancet. Oncology 2023; (24(3)):273-285 doi:10.1016/S1470-2045(23)00051-7.
PMID: 36858723
12
Therapeutic Strategies for the Management of Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Positive (HR+/HER2+) Breast Cancer: A Review of the Current Literature.
Thanopoulou E, Khader L, Caira M, et al.
Cancers 2020; (12(11)) doi:10.3390/cancers12113317.
PMID: 33182657
13
Breast cancer.
Harbeck N, Penault-Llorca F, Cortes J, et al.
Nature reviews. Disease primers 2019; (5(1)):66 doi:10.1038/s41572-019-0111-2.
PMID: 31548545

This page is for informational purposes only and does not constitute medical advice. Your oncology team should tailor surgery, medicines, radiation, and monitoring to your tumor features, health, and preferences.

Get notified when new evidence is published on HER2 positive breast carcinoma.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

Guide Contents